Neurofeedback From the Supplementary Motor Area for Tourette Syndrome

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05558566
Collaborator
National Institute of Mental Health (NIMH) (NIH)
64
1
2
50.6
1.3

Study Details

Study Description

Brief Summary

This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-time fMRI neurofeedback (NF) from a control region (for the control intervention).

Condition or Disease Intervention/Treatment Phase
  • Other: Neurofeedback from the SMA
  • Other: Neurofeedback from control region
N/A

Detailed Description

The training portion of this study involves three fMRI NF sessions, with six NF scans per session. NF scans alternate between up-regulate and down-regulate blocks in which participants are cued to increase or decrease activity in the target region while receiving feedback on activity in the region at the bottom of the screen in the form of a line graph. The experimental group receives feedback from the supplementary motor area (SMA) and the control group receives feedback from a control region of the brain.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Neurofeedback From the Supplementary Motor Area for Tourette Syndrome
Actual Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Dec 20, 2026
Anticipated Study Completion Date :
Jan 20, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Neurofeedback from the SMA

Other: Neurofeedback from the SMA
Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal

Active Comparator: Neurofeedback from control region

Other: Neurofeedback from control region
Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.

Outcome Measures

Primary Outcome Measures

  1. Change in symptoms after the intervention compared to baseline [Baseline, 4 days post-NF, 2 weeks post-NF, and 1 month post-NF]

    Symptom severity is assessed using the Yale Global Tic Severity Scale (YGTSS) before NF and at several time points in the month following the completion of NF training.

Secondary Outcome Measures

  1. Change in control over activity in the SMA target region during NF compared to baseline [Baseline and during NF]

    Control over the SMA is computed as the difference in the blood-oxygenation-level-dependent (BOLD) signal in SMA during up-regulate compared to down-regulate blocks. This measure is computed both in the NF scans and in the control task scans prior to the start of NF. Improvement in control for each subject is the difference of these two (i.e., control during NF minus control during pre-intervention control task scans).

Other Outcome Measures

  1. Changes in resting state functional connectivity to SMA in NF group [Baseline and one month post-NF]

    Functional connectivity is measured as temporal synchrony in the BOLD data in functional scans in which participants are just resting in the scanner. These scans are collected at baseline and one month after the neurofeedback training. Connectivity to the SMA will be computed for each time point and the change in the neurofeedback group will be examined and correlated with symptom improvement.

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 16 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Boys and girls, 10 to 16 years of age

  • A current diagnosis of Tourette Syndrome (TS) or chronic tic disorder, with active tics that can be executed without head movement, and a YGTSS score of at least 13

  • Currently stable medication treatment and no planned changes in medication for the duration of the study.

  • Family residence within 2 hours of Yale Medical Center with ability and willingness to attend assessment and fMRI visits.

  • Children and their parents are expected to be able to speak and understand spoken English in order to participate in a clinical assessment of TS and related psychopathology.

  • Subjects will be free of: 1) metal medical implants or braces, 2) pregnancy, and will have 3) a body weight of less than 250 lbs. and 4) no claustrophobia.

Exclusion Criteria:
  • Intelligence quotient below 80

  • Current diagnosis of autism spectrum disorder, bipolar or psychotic disorder or current suicidality

  • Significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, seizure disorder

  • Recently initiated psychotherapy. Participation in the study will not be allowed within 8 weeks of the initiation of psychotherapy. Ongoing, concurrent psychotherapy (that was initiated at least 8 weeks previously) for the child will be allowed, but parents will be asked not to initiate any new psychotherapy for the child during the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale University School of Medicine New Haven Connecticut United States 06520

Sponsors and Collaborators

  • Yale University
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Michelle Hampson, PhD, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT05558566
Other Study ID Numbers:
  • 2000033043
  • 1R01MH127147-01A1
First Posted:
Sep 28, 2022
Last Update Posted:
Nov 23, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2022